Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CanX
Toronto, Ontario, Canadacanxtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CanX is a biotechnology company focused on the development of novel cannabinoid-based therapeutics for the treatment of inflammatory and fibrotic diseases. The company leverages its expertise in cannabinoid receptor pharmacology to design small molecules that selectively target CB1 and CB2 receptors to modulate immune responses and tissue repair. CanX's lead programs are currently in the pre-clinical stage, with a focus on addressing high unmet medical needs in chronic pain and organ fibrosis. By optimizing the therapeutic potential of the endocannabinoid system, CanX aims to provide safer and more effective alternatives to current standard-of-care treatments.
- Therapeutic areas
- ImmunologyNeurologyOther
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on CanX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CanX.